Abstract
Research investigators are trained to be thorough, to find everything worth findings in their data. Having invested great time and effort in their studies, these scientists want and need to examine the data systematically and completely. In clinical experiments where there are multiple endpoints, investigators will examine the effect of therapy on each one, with the anticipated reward of identifying a therapy effect for the experiment’s primary endpoint. However, investigators are aware that there may be unanticipated findings in other analyses, that, unlike the primary endpoint analysis, are nonprospectively stated evaluations. Investigators believe that, like unsuspected pots of gold, these tantalizing surprises might lie just under the surface, hidden from view, waiting to be found. If the experiment demonstrated that an intervention reduces the incidence of heart attacks, then maybe there is a hidden relationship between marital status and heart attacks. Perhaps there is an unanticipated relationship between the patient’s astrologic sign and the occurrence of a heart attack? Sometimes it is not the investigator who is raising these questions. In the process of publication, reviewers of the manuscript will sometimes ask that additional analyses be carried out. These analyses can include considering the effect of the intervention in subsets of the data. Does the therapy work equally well in women and men? Does it work equally in different racial groups? What about in patients with a previous heart attack? These analyses are demanded by others, but are also not prospectively stated.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Mills, J.L. (1993) “Data torturing,” New Eng JMed. 329: 1196–1199.
The SHEP Cooperative Research Group. (1988) “Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension,” Journal of Clinical Epidemiology 41: 1197–1208.
Davis, B.R., Cutler, J.A., Gordon, D.J., Furberg, C.D., Wright, J.T., Cushman,C., Grimm, R.H., LaRosa, J., Whelton, P.K., Perry, H.M., Alderman, M.H., Ford, C.E., Oparil, S., Francis, C., Proscham, M., Pressel, S., Black, H.R., and Hawkins, C.M., for the ALLHAT Research Group. (1996) “Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial,” American Journal of Hypertension 9: 342–360.
Yusef, S., Wittes, J., Probstfield, J., and Tyroler, H.A., (1991) “Analysis and Interpretation of Treament Effects in Subgroups of Patients in Randomized Clinical Trials,” Journal of the American Medical Association 2266: 93–98.
Sacks, F.M., Pfeffer, M.A., Moyé, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G., Brown, L., Warnica, J.W., Arnold, J.M., Wun, C.C., Davis, B.R., and Braunwald, E., for the Cholesterol and recurrent Events Trial Investigators (1996) “The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels,” N Engl J Med 335: 1001–1009.
Lewis, S.J., Sacks, F.M., Mitchell, J.S., East, C., Glasser, S., Kell, S., Letterer, R., Limacher, M., Moyé, L.A., Rouleau, J.L., Pfeffer, M.A., and Braunwald, E., (1998) “Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial,” Journal of the American College of Cardiology 32: 140–146.
Sacks, F.M., Moyé, L.A., Davis, B.R., Cole, T.G., Rouleau, J.L., Nash, D.T., Pfeffer, M.A., and Braunwald, E. (1998) “Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial,” Circulation 97: 1446–1452.
Cohen, A.J. “Replication” Epidemiology 8: 341–343.
Beaglehole, R., Bonita, R. and Kjellström, T., (1993) Causation in epidemiology, Geneva: World Health Organization, pp. 71–81.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. (1998) “Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease with a broad range of initial cholesterol levels,” New Eng j Med 339: 1349–57.
Moyé, L.A., for the SAVE Cooperative Group (1991) “Rationale and Design of a Trial to Assess Patient Survival and Ventricular Enlargement after Myocardial Infarction,” Journal of the American College of Cardiology, 68: 70D - 79D.
Pfeffer, M.A., Brauwald, E., and Moyé L.A., (1992) “Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction—results of the Survival and Ventricular Enlargement Trial,” New England Journal of Medicine 327: 669–677.
Moyé, L.A., Pfeffer, M.A., Wun, C.C., and Davis, B.R., (1994) “Uniformity of Captopril Benefit in the Post Infarction Population: Subgroup Analysis in SAVE,” European Heart Journal 15: 2–8.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Moyé, L.A. (2000). Blind Guides for Explorers: P Values, Subgroups and Data Dredging. In: Statistical Reasoning in Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-3292-4_12
Download citation
DOI: https://doi.org/10.1007/978-1-4757-3292-4_12
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-98933-4
Online ISBN: 978-1-4757-3292-4
eBook Packages: Springer Book Archive